Certified by Founder Lodge
Glycomine Inc.
United States - San Carlos, California
START UP
1 Disclosed Funding Rounds $115,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| April, 17 ,2025 | Series C | $115,000,000 |
Advent Life Sciences
Abingworth
RiverVest Venture Partners
CTI Life Sciences Fund
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Helex | $3,500,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
catalyx space | $5,400,000 | (Nov 4, 2025)
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
